Evidence map›Paper›PMID 30012420›Full record

ArticleJournal of proteomics2018

Embryonic atrazine exposure elicits proteomic, behavioral, and brain abnormalities with developmental time specific gene expression signatures.

Katharine A Horzmann, Leeah S Reidenbach, Devang H Thanki, Anna E Winchester, Brad A Qualizza, Geoffrey A Ryan, Kaitlyn E Egan, Victoria E Hedrick, Tiago J P Sobreira, Samuel M Peterson and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of proteomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Katharine A HorzmannSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Leeah S ReidenbachSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Devang H ThankiSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Anna E WinchesterSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Brad A QualizzaSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Geoffrey A RyanSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Kaitlyn E EganSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Victoria E HedrickBindley Bioscience Center, Discovery Park, Purdue University, West Lafayette, IN 47907, United States.
Tiago J P SobreiraBindley Bioscience Center, Discovery Park, Purdue University, West Lafayette, IN 47907, United States.
Samuel M PetersonSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Gregory J WeberSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Sara E Wirbisky-HershbergerSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States.
Maria S SepúlvedaForestry and Natural Resources, Purdue University, West Lafayette, IN 47907, United States.
Jennifer L FreemanSchool of Health Sciences, Purdue University, West Lafayette, IN 47907, United States; Purdue Center for Cancer Research, Purdue University, West Lafayette, IN 47907, United States. Electronic address: jfreema@purdue.edu.
Purdue University West Lafayette · USCenter for Cancer Research · US

Funding

Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Molecular biomarkers of exposure to an endocrine disrupting herbicideR15ES019137 · NIEHS · PURDUE UNIVERSITY · PI FREEMAN, JENNIFER L. · 2010 to 2013
$891k
NCATS NIH HHS UL1 TR001108NIEHS NIH HHS R15 ES019137NIOSH CDC HHS T42 OH008672
6 · The paper itself

Abstract

Atrazine (ATZ), the second most commonly used herbicide in the United States, is an endocrine disrupting chemical linked to cancer and a common drinking water contaminant. This study further investigates ATZ-related developmental toxicity by testing the following hypotheses in zebrafish: the effects of embryonic ATZ exposure are dependent on timing of exposure; embryonic ATZ exposure alters brain development and function; and embryonic ATZ exposure changes protein abundance in carcinogenesis-related pathways. After exposing embryos to 0, 0.3, 3, or 30 parts per billion (ppb) ATZ, we monitored the expression of cytochrome P450 family 17 subfamily A member 1 (cyp17a1), glyoxalase I (glo1), ring finger protein 14 (rnf14), salt inducible kinase 2 (sik2), tetratricopeptide domain 3 (ttc3), and tumor protein D52 like 1 (tpd52l1) at multiple embryonic time points to determine normal expression and if ATZ exposure altered expression. Only cyp17a1 had normal dynamic expression, but ttc3 and tpd52l1 had ATZ-related expression changes before 72 h. Larvae exposed to 0.3 ppb ATZ had increased brain length, while larvae exposed to 30 ppb ATZ were hypoactive. Proteomic analysis identified altered protein abundance in pathways related to cellular function, neurodevelopment, and genital-tract cancer. The results indicate embryonic ATZ toxicity involves interactions of multiple pathways. SIGNIFICANCE: This is the first report of proteomic alterations following embryonic exposure to atrazine, an environmentally persistent pesticide and common water contaminant. Although the transcriptomic alterations in larval zebrafish with embryonic atrazine exposure have been reported, neither the time at which gene expression changes occur nor the resulting proteomic changes have been investigated. This study seeks to address these knowledge gaps by evaluating atrazine's effect on gene expression through multiple time points during embryogenesis, and correlating changes in gene expression to pathological alterations in brain length and functional changes in behavior. Finally, pathway analysis of the proteomic alterations identifies connections between the molecular changes and functional outcomes associated with embryonic atrazine exposure.

Indexed as

ProteomicsAnimalsAtrazineBrainDose-Response Relationship, DrugEmbryonic DevelopmentEmbryo, NonmammalianEndocrine DisruptorsGene Expression Regulation, DevelopmentalHerbicidesLarvaProteinsWater Pollutants, ChemicalZebrafishAtrazineEndocrine DisruptorsHerbicidesProteinsWater Pollutants, ChemicalAtrazineBehaviorDevelopmental toxicityGene expressionProteomicsZebrafish

Identifiers

PMID30012420
PMCPMC6193558
OpenAlexW2883892617

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.